RE:RE:RE:RE:Exercise of Options I have heard many cases where unless there's some extenuating circumstances (which can still be the case here) a CEO will "strongly urge" his management team not to sell until a particular strategic objective has been attained...say, a milestone like commencing Phase 2, or even further out like FDA approval. He can't hold anyone to it legally, but he can make it known he would look at a sale highly negatively and so would the market. You need to eat what you cook and align with your investors and Board paying your salary. A question for IR ...was CEO ok with the share sale from his officer just prior to learning if the oncology drug shows efficacy in a broader set of patients?
PWIB123 wrote: Why aren't those filings showing on Sedar or Edgar? Sometimes companies will put an explanation in the description of an insider trade, such as donated to charity or forfeiture of shares to pay taxes from shareholder compensation plan.
The timing of this insider sell couldn't be any worse. I have been so excited about the near-term prospects, but this definitely tempers my hope...a lot. Who would sell if they thought there was huge upside in the near term? I don't care what your personal circumstances are, you find a way. This doens't look good at all!
palinc2000 wrote: This is really crappy at least optically
I dont want to spend the time to search what was the expiration date of the options but even if the expiry date was close he could have exercised now and not sell That would have been an out of pocket cost of 7600 $ now plus additional income taxes in April 2022 of less than 10000$
I hope this is not another Lyne moment!!!